Companies /Basic Materials

Celanese Corp - Series A

NYSE: CE Chemicals
$45.16
▼ $1.50 (−3.21%) today
Markets closed · 6:33pm ET

Q1 2025 Earnings

Reported May 5, 2025, 5:06pm ET · SEC source
$0.57
Beat +47.82%
EPS · est. $0.39
$2.4B
Beat +5.54%
Revenue · est. $2.3B
+5.9%
Beating market
CE vs S&P since report
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
−4%0+4%May 5May 6report 5:06pm ETearnings+0.0%+6.5%
−4%0+4%May 5May 6earnings+0.0%+6.5%
CE +6.5%S&P 500 +0.0%
−4%0+4%May 5May 6report 5:06pm ETearnings+0.1%+6.5%
−4%0+4%May 5May 6earnings+0.1%+6.5%
CE +6.5%NASDAQ +0.1%
0+8%+16%May 5May 13report 5:06pm ETearnings+4.2%+16.2%
0+8%+16%May 5May 13earnings+4.2%+16.2%
CE +16.2%S&P 500 +4.2%
0+8%+16%May 5May 13report 5:06pm ETearnings+6.3%+16.2%
0+8%+16%May 5May 13earnings+6.3%+16.2%
CE +16.2%NASDAQ +6.3%
+9.56%
Day of report
−1.22%
Next session
+8.97%
One week
+13.07%
30 days

S&P 500 over the same 30 days: +7.22%.

Did CE Beat Earnings? Q1 2025 Results

Celanese delivered a stronger-than-expected first quarter, posting adjusted EPS of $0.57 against a consensus estimate of $0.39, a beat of 47.82%, even as the specialty chemicals company continued to navigate a choppy demand environment across automotive, paints, and construction markets. Revenue came in at $2.39 billion, topping estimates by 5.54%, though the figure still represented an 8.5% decline year-over-year as softer volumes and modest pricing pressure weighed on results. The primary driver of the earnings outperformance was favorable mix within Engineered Materials, where stronger-than-anticipated medical implant grade sales and productivity-related cost reductions helped offset broader demand weakness. Celanese also completed roughly $2.60 billion in registered note offerings during the quarter, improving its near-term debt maturity profile as it pursues deleveraging against net debt of $11.83 billion. Looking ahead, management guided Q2 adjusted EPS of $1.30 to $1.50, anticipating tailwinds from a resuming Chinese partner dividend, normalizing acetate tow orders, and modest automotive volume recovery, while targeting full-year free cash flow of $700 to $800 million.

Key Takeaways
  • Favorable mix in Engineered Materials from stronger medical implant grade sales
  • Productivity gains lowering costs in Engineered Materials
  • 2% sequential volume increase at the total company level
  • Delayed Chinese partner dividend payment shifted to Q2 due to change in Chinese law
  • Higher energy costs in Acetyl Chain
  • Greater than anticipated delays in acetate tow order timing

“Our end-markets in the first quarter exhibited dynamics similar to the fourth quarter, and demand in our businesses developed mostly as we expected. While tariffs are a constant topic, we saw no direct impact in the first quarter. No matter how the demand environment develops over the remainder of the year, our mission is unchanged. We intend to continue driving productivity and earnings growth through execution of our three key priorities, and are taking aggressive actions to generate cash, reduce costs, and drive growth through our two differentiated business models.”

Celanese CEO, on the earnings call

Forward Guidance & Outlook

For Q2 2025, Celanese anticipates adjusted EPS of $1.30 to $1.50, supported by tailwinds from non-recurring Q1 items not repeating, including the resumption of the Chinese partner dividend in the Acetyl Chain, slight automotive volume recovery (especially in the U.S. and China), and normalization of acetate tow orders. Management does not anticipate direct tariff impacts in Q2 due to mitigation preparations and global production network flexibility. For full-year 2025, the company expects $700 to $800 million of free cash flow assuming no meaningful downturn in demand, though tariff-related uncertainties make full-year earnings prediction difficult. The effective adjusted tax rate is anticipated at 9% for the full year.

CE YoY Financials

Q1 2025 vs Q1 2024 · SEC filings Q1 2024 Q1 2025
$0$800.0M$1.6B$2.4B$2.6B$2.4BRevenue$554.0M$476.0MGross Profit$210.0M$168.0MOperating Income
$0$800.0M$1.6B$2.4BRevenueGross ProfitOperating Income

CE Revenue by Segment

Engineered Materials$1.3B
Acetyl Chain$1.1B

Figures from SEC filings and company reports. Not investment advice.